Optical and clinical outcomes of a new diffractive trifocal intraocular lens.

PurposeTo optically characterize and clinically evaluate the new trifocal AT ELANA 841P intraocular lens (IOL).MethodsThe optical imaging performance was assessed using an on-bench model eye through the Through-Focus Modulation Transfer Function Area (TF-MTFa) from +1.00 to -3.50D. The clinical study included manifest refraction, uncorrected (UDVA) and corrected (CDVA) distance visual acuities, distance-corrected intermediate (DCIVA) and near visual acuity (DCNVA), binocular photopic and mesopic contrast sensitivity (CS) and binocular defocus curve. Postoperative evaluation was performed 3 months after surgery.ResultsOptimal optical quality is observed at the distance focus on the TF-MTFa curve. From there, optical quality continuously degrades, initially rapid up to approximately -0.75D, then much slower extending to -2.0D. Subsequently, optical quality improves before a decline from -2.75D. The clinical study involved 40 patients. The mean postoperative monocular UDVA and CDVA were 0.04 ± 0.05 and 0.01 ± 0.02 logMAR, respectively. All eyes achieved a monocular UDVA of 0.2 logMAR or better and a monocular CDVA of 0.1 logMAR or better. All patients reached a binocular DCNVA of 0.2 logMAR or better, and 95% achieved a DCIVA of 0.2 logMAR or better. The defocus curve yielded a range from +0.50 to -2.5D, in which the mean visual acuity was 0.1 logMAR or better. The binocular distance CS was within normal limits.ConclusionsThe implantation of the new AT ELANA IOL provided a satisfactory range of visual quality from distance to near, in excellent agreement with the IOL optical performance obtained with the on-bench model eye.